Penumbra, Inc. (PEN)
NYSE • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Penumbra, Inc. keeps $9 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Penumbra’s second fiscal quarter of 2026, reported July 30, 2026, was a mixed print: EPS of $0.88 missed the $1.16 estimate by about 24%, even as revenue of about $390.0 million edged the $389.6 million consensus by roughly 0.1%. Revenue rose about 15% from $339.5 million a year ago, and gross margin held near 68% while operating margin came in around 11%, with gross profit at about $264.9 million and operating income of roughly $41.0 million. Net income fell about 23% to roughly $34.8 million from $45.3 million a year ago, while operating cash flow was $46.1 million. Consensus for the next period calls for EPS of $1.26 on revenue of $401.5 million.
About Penumbra, Inc.
Penumbra, Inc. develops and sells medical technology for vascular and neuro interventions, trading on the NYSE as PEN. In healthcare, it focuses on devices used to remove clots, treat aneurysms and other lesions, and support neurosurgical evacuation, with $1.4 billion in FY2025 revenue.
Today's Snapshot
PEN opened slightly lower at 319.17, in line with a flat sector.
Trading Volume
Below 10d avg (265.6K)
17.1K
vs S&P 500 Today
Outperforming Market
+0.52%
Updated: September 10, 2026 at 14:37 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$313.63 - $322.09Sell
- RSI (14)38.95Neutral
- Stochastic %K (14, 3, 3)4.19Buy
- MACD Level (12, 26)-0.72Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.